$91.12
+1.4%IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Chief Commercial Officer
Compensation
$105,432
Chief Financial Officer & Corporate Secretary
Compensation
$574,820
Controller
Executive Vice President of Continuous Improvement & Information Technology
Founder, Chairman, Chief Executive Officer & President
Compensation
$689,580
Vice President of Research & Development
Compensation
$354,946
Vice President of Worldwide Sales & Marketing
Compensation
$446,151
During the last 12 months, insiders have sold $9.52M worth of IRMD shares, with no buying activity reported.
0
0.00
43.2K
4.11M
-4.1M
-$4.11M
0
0.00
48.3K
4.71M
-4.7M
-$4.71M
0
0.00
8.1K
702.27K
-702K
-$702K
0
0.00
0
0.00
+0
+$0
No buying activity
Susi Roger E.
Director, 10 Percent Owner, Officer: Ceo, President, Chairman
$7.72M
Glenn John
Officer: Chief Financial Officer
$1.41M
Hawkins James B
Director
$290K
Allen Monty K
Director
$100K
Strong bearish signal with $9.52M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
4 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
IRMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 23, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 19, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 15, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 10, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 11, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 12, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 14, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 27, 2018 | June 08, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 28, 2017 | June 09, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.